Patents Assigned to Lennham Pharmaceuticals, Inc.
  • DEUTERATED CAFFEINE AND USES THEREOF
    Publication number: 20200390128
    Abstract: Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, diet supplements) comprising deuterated caffeine. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.
    Type: Application
    Filed: July 17, 2020
    Publication date: December 17, 2020
    Applicant: Lennham Pharmaceuticals, Inc.
    Inventor: Bradford C. Sippy
  • Deuterated caffeine and uses thereof
    Patent number: 10765130
    Abstract: Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, diet supplements) comprising deuterated caffeine. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: September 8, 2020
    Assignee: Lennham Pharmaceuticals, Inc.
    Inventor: Bradford C. Sippy
  • Deuterated caffeine and uses thereof
    Patent number: 10582716
    Abstract: Provided herein are compositions (e.g., pharmaceutical compositions, nutraceutical compositions, foods, beverages, cosmetic compositions, diet supplements) comprising deuterated caffeine. The provided compositions may be useful for treating and/or preventing various diseases and conditions, such as obesity, causing weight loss, increasing metabolic rate, reducing appetite, increasing energy expenditure, increasing urine output, increasing sodium excretion, reducing edema, a pain disorder, apnea, hypotension, an encephalopathy, a neurological or psychiatric disorder, and an inflammatory disorder.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: March 10, 2020
    Assignee: Lennham Pharmaceuticals, Inc.
    Inventor: Bradford C. Sippy